SNCE(Delisted)
Science 37 Holdings·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SNCE
Science 37 Holdings, Inc.
A leading provider of technology-based solutions that enable agile clinical trials and decentralized approaches on behalf of biopharmaceutical sponsors
800 Park Offices Drive, Suite 3606, Research Triangle Park, North Carolina
--
Science 37 Holdings, Inc., was established on December 18, 2019 and is a Delaware corporation. Science 37 supports clinical research — making it easier for patients and providers to participate and accelerating the development of new and innovative treatments designed to improve and extend patient life. As one of the early developers of decentralized clinical trials, Science 37 creates an operating system (OS) for present and future clinical research. The company enables workflow orchestration, evidence generation and data coordination on a unified platform — configurable to support any research and integrated with its extensive network of telemedicine investigators, mobile nurses, remote coordinators, patient communities and connected devices.
Company Financials
EPS
SNCE has released its 2023 Q3 earnings. EPS was reported at -0.05, versus the expected -0.07, beating expectations. The chart below visualizes how SNCE has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SNCE has released its 2023 Q3 earnings report, with revenue of 14.89M, reflecting a YoY change of -8.38%, and net profit of -13.92M, showing a YoY change of 40.82%. The Sankey diagram below clearly presents SNCE's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
